Global Markets Direct, Dec 2010, Pages: 37
from company and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Adamas Pharmaceuticals, Inc. - Brief company overview including business description, key
Global Markets Direct, Dec 2010, Pages: 35
Development To World Health Organization Advisory Committee On Variola Virus Research
Nov 07, 2010: Chimerix Reaffirms Commitment To CMX001 As Medical Countermeasure For Smallpox And Broad-Spectrum Antiviral
CME Group, Nov 2008
of Internal Medicine. The program is also intended for physicians who are interested in an intensive, broad-scope review of Infectious Disease topics. - The nation’s premier infectious disease board review
John Wiley and Sons Ltd, Sep 2011, Pages: 456
Complete, up-to-date coverage of the broad area of nucleic acid chemistry and biology.
Assembling contributions from a collection of authors with expertise in all areas of nucleic acids, medicinal
Global Markets Direct, Oct 2011, Pages: 101
releases, both from Quigley Pharma, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Quigley Pharma, Inc. - Brief Quigley Pharma, Inc. overview
GlobalData, Nov 2010, Pages: 70
From Autoimmune Disease Program At ACR 74th Annual Scientific Meeting
Oct 30, 2010: Idera Presents Phase I Data On IMO-2125 Demonstrating Induction Of BroadAntiviral Immune Response In Null-Responder
Global Markets Direct, Nov 2010, Pages: 70
Autoimmune Disease Program At ACR 74th Annual Scientific Meeting
Oct 30, 2010: Idera Presents Phase I Data On IMO-2125 Demonstrating Induction Of BroadAntiviral Immune Response In Null-Responder HCV
Global Markets Direct, March 2011, Pages: 42
On Variola Virus Research
Nov 07, 2010: Chimerix Reaffirms Commitment To CMX001 As Medical Countermeasure For Smallpox And Broad-Spectrum Antiviral Agent
Aug 04, 2010: Tapimmune Signs
Espicom Business Intelligence Ltd, Oct 2009, Pages: 290
and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic
Life Science Intelligence, Inc., Dec 2009, Pages: 1763
-2009 Elsevier/Medtech Insight In3 investor/partnering conference; or have been identified by LSI's in-house research team from 2004 thru 2009.
Coverage includes innovations in a broad spectrum of medical
John Wiley and Sons Ltd, Oct 2011, Pages: 390
.2 Overview of Process for Transforming Peptides to Peptidomimetics
1.3 HCMV Protease
1.3.1 HCMV Protease: Identification and Characterization of Antiviral Inhibitors Targeting the Serine Protease Domain
GlobalData, Sep 2011, Pages: 42
and infectious disease. Several of its antiviral programs, include Ebola, Marburg, Junín and H1N1, are been funded by the U.S. Government. It has 189 patents both foreign and domestic and 181 pending patent
Global Markets Direct, Sep 2011, Pages: 69
935 By Novartis.
Oct 30, 2010: Idera Presents Phase I Data On IMO-2125 Demonstrating Induction Of BroadAntiviral Immune Response In Null-Responder HCV Patients At AASLD Meeting 2010
Oct 29, 2010
John Wiley and Sons Ltd, March 2008, Pages: 272
such as a brief survey of immunology, to help guide the readers understanding.
This book is appropriate for a broad readership, starting with curious and thoughtful college undergraduates and reaching beyond
ICON Group International, Jan 2011, Pages: 344
Market Potential Estimation Methodology Overview This study covers the world outlook for pharmaceutical preparations for human use affecting parasitic and infectious diseases excluding diagnostics
ICON Group International, Jan 2011, Pages: 145
agents, anthelminics 325412P117 Anti_infective agents, systemic antibiotic preparations, broad and medium spectrum, tetracyclines (including chlortetracycline and congeners) 325412P121 Anti
ICON Group International, May 2009, Pages: 344
Market Potential Estimation Methodology Overview This study covers the world outlook for pharmaceutical preparations for human use affecting parasitic and infectious diseases excluding diagnostics
